MOLN MOLECULAR PARTNERS AG IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1745114 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 0 | 4.97M |
| R&D expense | 40.19M | 48.60M |
| SG&A expense | 15.24M | 17.58M |
| Operating income | -58.12M | -61.22M |
| Interest expense | 5.05M | 38,000 |
| Pretax income | -61.65M | -54.04M |
| Income tax | 2,000 | 2,000 |
| Net income | -61.65M | -54.04M |
| EBITDA | -55.98M | -58.85M |
| EPS (basic) | -1.65 | -1.59 |
| EPS (diluted) | -1.65 | -1.59 |
| Weighted avg. shares (diluted) | 37.27M | 34.03M |
| Balance sheet | ||
| Cash & equivalents | 82.65M | 63.87M |
| Short-term investments | 10.40M | 85.56M |
| Receivables | 1.83M | 2.32M |
| Current assets | 96.88M | 154.28M |
| PP&E, netmay include right-of-use assets (IFRS) | 5.23M | 4.20M |
| Intangibles | 2,000 | 49,000 |
| Total assets | 102.11M | 158.53M |
| Current liabilities | 11.03M | 10.79M |
| Total liabilities | 21.77M | 16.89M |
| Shareholders' equity | 80.33M | 141.64M |
| Shares outstanding | 40.37M | 40.36M |
| Cash flow statement | ||
| Operating cash flow | -51.26M | -59.25M |
| Capital expenditure | 714,000 | 705,000 |
| Free cash flow | -51.97M | -59.95M |
| Investing cash flow | 72.55M | 40.49M |
| Financing cash flow | -1.15M | 14.43M |
| Depreciation & amortization | 2.14M | 2.37M |
| Stock-based compensation | 4.42M | 4.11M |
| Share buybacks | — | 0 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.